Activities per year
- 1 - 50 out of 78 results
Search results
-
Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar. Déry JP, Mahaffey KW, Tricoci P, White HD, Podder M, Westerhout CM, Moliterno DJ, Harrington RA, Chen E, Strony J, Van de Werf F, Ziada KM, Held C, Aylward PE, Armstrong PW, Rao SV. Catheter Cardiovasc Interv. 2016 Aug;88(2):163-73. doi: 10.1002/ccd.26335. Epub 2015 Dec 23. PMID: 26698636 Clinical Trial.
Erin Morton (Other)
2016Activity: Other activity types › Other
-
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). Mahaffey KW, Huang Z, Wallentin L, Storey RF, Jennings LK, Tricoci P, White HD, Armstrong PW, Aylward PE, Moliterno DJ, Van de Werf F, Chen E, Leonardi S, Rorick T, Held C, Strony J, Harrington RA. Am J Cardiol. 2014 Mar 15;113(6):936-44. doi: 10.1016/j.amjcard.2013.11.052. Epub 2013 Dec 25. PMID: 24444781 Clinical Trial.
Erin Morton (Other)
2014Activity: Other activity types › Other
-
Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS. Pagidipati NJ, Zheng Y, Green JB, McGuire DK, Mentz RJ, Shah S, Aschner P, Delibasi T, Rodbard HW, Westerhout CM, Holman RR, Peterson ED; TECOS Study Group. Am Heart J. 2020 Jan;219:47-57. doi: 10.1016/j.ahj.2019.09.016. Epub 2019 Oct 20. PMID: 31707324 Clinical Trial.
Erin Morton (Other)
2019Activity: Other activity types › Other
-
Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease. Stewart RAH, Held C, Krug-Gourley S, Waterworth D, Stebbins A, Chiswell K, Hagstrom E, Armstrong PW, Wallentin L, White H. J Am Heart Assoc. 2019 Apr 2;8(7):e010641. doi: 10.1161/JAHA.118.010641. PMID: 30897999 Clinical Trial.
Erin Morton (Participant)
2019Activity: Other activity types › Other
-
Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. Sharma A, Green JB, Dunning A, Lokhnygina Y, Al-Khatib SM, Lopes RD, Buse JB, Lachin JM, Van de Werf F, Armstrong PW, Kaufman KD, Standl E, Chan JCN, Distiller LA, Scott R, Peterson ED, Holman RR; TECOS Study Group. Diabetes Care. 2017 Dec;40(12):1763-1770. doi: 10.2337/dc17-1091. Epub 2017 Oct 6. PMID: 28986504
Erin Morton (Other)
2017Activity: Other activity types › Other
-
Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. Held C, White HD, Stewart RAH, Davies R, Sampson S, Chiswell K, Silverstein A, Lopes RD, Heldestad U, Budaj A, Mahaffey KW, Wallentin L; STABILITY Investigators. Am Heart J. 2019 Feb;208:65-73. doi: 10.1016/j.ahj.2018.10.010. Epub 2018 Nov 7. PMID: 30572273 Clinical Trial.
Erin Morton (Other)
2019Activity: Other activity types › Other
-
Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis. Diehl P, Bode C, Duerschmied D. Ther Clin Risk Manag. 2015 Aug 3;11:1133-8. doi: 10.2147/TCRM.S55469. eCollection 2015. PMID: 26346960. Review.
Erin Morton (Other)
2015Activity: Other activity types › Other
-
Coronary artery disease: Darapladib fails to improve the STABILITY of CAD. Roberts A. Nat Rev Cardiol. 2014 Jun;11(6):310. doi: 10.1038/nrcardio.2014.50. Epub 2014 Apr 15. PMID: 24736761
Erin Morton (Other)
2014Activity: Other activity types › Other
-
Darapladib for preventing ischemic events in stable coronary heart disease. STABILITY Investigators, White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, Budaj A, Harrington RA, Steg PG, Ardissino D, Armstrong PW, Avezum A, Aylward PE, Bryce A, Chen H, Chen MF, Corbalan R, Dalby AJ, Danchin N, De Winter RJ, Denchev S, Diaz R, Elisaf M, Flather MD, Goudev AR, Granger CB, Grinfeld L, Hochman JS, Husted S, Kim HS, Koenig W, Linhart A, Lonn E, López-Sendón J, Manolis AJ, Mohler ER 3rd, Nicolau JC, Pais P, Parkhomenko A, Pedersen TR, Pella D, Ramos-Corrales MA, Ruda M, Sereg M, Siddique S, Sinnaeve P, Smith P, Sritara P, Swart HP, Sy RG, Teramoto T, Tse HF, Watson D, Weaver WD, Weiss R, Viigimaa M, Vinereanu D, Zhu J, Cannon CP, Wallentin L. N Engl J Med. 2014 May 1;370(18):1702-11. doi: 10.1056/NEJMoa1315878. Epub 2014 Mar 30. PMID: 24678955 Clinical Trial.
Erin Morton (Other)
2014Activity: Other activity types › Other
-
Differential induction of micronuclei in peripheral lymphocytes and exfoliated urothelial cells of workers exposed to 4,4’-methylenebis-(2-chloroaniline)(MOCA) and bitumen fumes
Erin Morton (Speaker) & J W Edwards (Speaker)
2001Activity: Talk or presentation types › Oral presentation
-
Differential induction of micronuclei in peripheral lymphocytes and exfoliated urothelial cells of workers exposed to 4,4’-methylenebis-(2-chloroaniline)(MOCA) and bitumen fumes. Murray, E.B. and Edwards, J.W. (2005). Reviews on Environmental Health 20(3): 163-176. 10.1515/REVEH.2005.20.3.163
Erin Morton (Other)
2005Activity: Other activity types › Other
-
Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. Armaganijan LV, Alexander KP, Huang Z, Tricoci P, Held C, Van de Werf F, Armstrong PW, Aylward PE, White HD, Moliterno DJ, Wallentin L, Chen E, Harrington RA, Strony J, Mahaffey KW, Lopes RD. Am Heart J. 2016 Aug;178:176-84. doi: 10.1016/j.ahj.2016.05.012. Epub 2016 Jun 9. PMID: 27502866
Erin Morton (Other)
2016Activity: Other activity types › Other
-
Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Davis TME, Mulder H, Lokhnygina Y, Aschner P, Chuang LM, Raffo Grado CA, Standl E, Peterson ED, Holman RR; TECOS Study Group. Diabetes Obes Metab. 2018 Jun;20(6):1427-1434. doi: 10.1111/dom.13242. Epub 2018 Feb 28. PMID: 29405540 Clinical Trial.
Erin Morton (Other)
2018Activity: Other activity types › Other
-
Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. Andrews J, Janssan A, Nguyen T, Pisaniello AD, Scherer DJ, Kastelein JJ, Merkely B, Nissen SE, Ray K, Schwartz GG, Worthley SG, Keyserling C, Dasseux JL, Butters J, Girardi J, Miller R, Nicholls SJ. Cardiovasc Diagn Ther. 2017 Feb;7(1):45-51. doi: 10.21037/cdt.2017.01.01. PMID: 28164012; PMCID: PMC5253449. H-index
Erin Morton (Other)
2017Activity: Other activity types › Other
-
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group. N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. PMID: 26052984 Clinical Trial.
Erin Morton (Other)
2015Activity: Other activity types › Other
-
Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. Tricoci P, Neely M, Whitley MJ, Edelstein LC, Simon LM, Shaw C, Fortina P, Moliterno DJ, Armstrong PW, Aylward P, White H, Van de Werf F, Jennings LK, Wallentin L, Held C, Harrington RA, Mahaffey KW, Bray PF. Blood Cells Mol Dis. 2018 Sep;72:37-43. doi: 10.1016/j.bcmd.2018.07.004. Epub 2018 Jul 21. PMID: 30055940. Clinical Trial.
Erin Morton (Other)
2018Activity: Other activity types › Other
-
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. Storey RF, Kotha J, Smyth SS, Moliterno DJ, Rorick TL, Moccetti T, Valgimigli M, Dery JP, Cornel JH, Thomas GS, Huber K, Harrington RA, Hord E, Judge HM, Chen E, Strony J, Mahaffey KW, Tricoci P, Becker RC, Jennings LK. Thromb Haemost. 2014 May 5;111(5):883-91. doi: 10.1160/TH13-07-0624. Epub 2014 Jan 9. PMID: 24402559 Clinical Trial.
Erin Morton (Other)
2014Activity: Other activity types › Other
-
Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery. van Diepen S, Tricoci P, Podder M, Westerhout CM, Aylward PE, Held C, Van de Werf F, Strony J, Wallentin L, Moliterno DJ, White HD, Mahaffey KW, Harrington RA, Armstrong PW. J Am Heart Assoc. 2015 Dec 15;4(12):e002546. doi: 10.1161/JAHA.115.002546. PMID: 26672080 Clinical Trial.
Erin Morton (Other)
2015Activity: Other activity types › Other
-
EurekaAlert! media publication - World-first cardio trial shows shorter wait times and admissions
Erin Morton (Other)
3 Sep 2019Activity: Other activity types › Other
-
European Society of Cardiology press release - RAPID-TnT trial
Erin Morton (Other)
3 Sep 2019Activity: Other activity types › Other
-
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). Cornel JH, Tricoci P, Lokhnygina Y, Moliterno DJ, Wallentin L, Armstrong PW, Aylward PE, Clare RM, Chen E, Leonardi S, Van de Werf F, White HD, Held C, Strony J, Mahaffey KW, Harrington RA. Am J Cardiol. 2015 May 15;115(10):1325-32. doi: 10.1016/j.amjcard.2015.02.043. Epub 2015 Feb 18. PMID: 25776457 Clinical Trial.
Erin Morton (Other)
2015Activity: Other activity types › Other
-
Health Translation SA media publication - World-first trial reduces ED wait times and hospital admissions
Erin Morton (Other)
17 Sep 2019Activity: Other activity types › Other
-
Hospital and Healthcare media publication - No need to wait for chest pain diagnosis
Erin Morton (Other)
10 Sep 2019Activity: Other activity types › Other
-
Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. Held C, White HD, Stewart RAH, Budaj A, Cannon CP, Hochman JS, Koenig W, Siegbahn A, Steg PG, Soffer J, Weaver WD, Östlund O, Wallentin L; STABILITY Investigators. J Am Heart Assoc. 2017 Oct 24;6(10):e005077. doi: 10.1161/JAHA.116.005077. PMID: 29066452. Clinical Trial.
Erin Morton (Other)
2017Activity: Other activity types › Other
-
Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. Batra G, Ghukasyan Lakic T, Lindbäck J, Held C, White HD, Stewart RAH, Koenig W, Cannon CP, Budaj A, Hagström E, Siegbahn A, Wallentin L; STABILITY Investigators. JAMA Cardiol. 2021 Dec 1;6(12):1440-1445. doi: 10.1001/jamacardio.2021.3079. PMID: 34431970 Clinical Trial.
Erin Morton (Other)
2021Activity: Other activity types › Other
-
International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. Bhatt AS, Luo N, Solomon N, Pagidipati NJ, Ambrosio G, Green JB, McGuire DK, Standl E, Cornel JH, Halvorsen S, Lopes RD, White HD, Holman RR, Peterson ED, Mentz RJ; TECOS Study Group. Am Heart J. 2019 Dec;218:57-65. doi: 10.1016/j.ahj.2019.08.016. Epub 2019 Aug 28. PMID: 31707329 Clinical Trial.
Erin Morton (Other)
2019Activity: Other activity types › Other
-
Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS. De Ferrari GM, Stevens SR, Ambrosio G, Leonardi S, Armstrong PW, Green JB, Wamil M, Holman RR, Peterson ED; TECOS Study Group. Am Heart J. 2020 Feb;220:82-88. doi: 10.1016/j.ahj.2019.11.005. Epub 2019 Nov 13. PMID: 31790905 Clinical Trial.
Erin Morton (Other)
2020Activity: Other activity types › Other
-
MedPage Today media publication - ESC Late-Breakers: BIOSTEMI; DANAMI-2; RAPID-TnT
Erin Morton (Other)
3 Sep 2019Activity: Other activity types › Other
-
Medscape media publication - RAPID-TnT Supports 0/1-Hour Troponin T protocol, but With a Wrinkle
Erin Morton (Other)
6 Sep 2019Activity: Other activity types › Other
-
Pancreatic Safety of Sitagliptin in the TECOS Study. Buse JB, Bethel MA, Green JB, Stevens SR, Lokhnygina Y, Aschner P, Grado CR, Tankova T, Wainstein J, Josse R, Lachin JM, Engel SS, Patel K, Peterson ED, Holman RR; TECOS Study Group. Diabetes Care. 2017 Feb;40(2):164-170. doi: 10.2337/dc15-2780. Epub 2016 Sep 14. PMID: 27630212. Clinical Trial.
Erin Morton (Other)
2016Activity: Other activity types › Other
-
PAR-1 antagonist vorapaxar favorably improves global thrombotic status in patients with coronary disease. Rosser G, Tricoci P, Morrow D, Christopoulos C, Niespialowska-Steuden MN, Kozarski R, Wilcox R, Gorog DA. J Thromb Thrombolysis. 2014 Nov;38(4):423-9. doi: 10.1007/s11239-014-1075-4. PMID: 24676931 Clinical Trial.
Erin Morton (Other)
2014Activity: Other activity types › Other
-
Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib. Yeo A, Li L, Warren L, Aponte J, Fraser D, King K, Johansson K, Barnes A, MacPhee C, Davies R, Chissoe S, Tarka E, O'Donoghue ML, White HD, Wallentin L, Waterworth D. PLoS One. 2017 Jul 28;12(7):e0182115. doi: 10.1371/journal.pone.0182115. eCollection 2017. PMID: 28753643.
Erin Morton (Other)
2017Activity: Other activity types › Other
-
Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. Stewart RAH, Held C, Hadziosmanovic N, Armstrong PW, Cannon CP, Granger CB, Hagström E, Hochman JS, Koenig W, Lonn E, Nicolau JC, Steg PG, Vedin O, Wallentin L, White HD; STABILITY Investigators. J Am Coll Cardiol. 2017 Oct 3;70(14):1689-1700. doi: 10.1016/j.jacc.2017.08.017. PMID: 28958324 Clinical Trial.
Erin Morton (Other)
2017Activity: Other activity types › Other
-
Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study. Wallentin L, Eriksson N, Olszowka M, Grammer TB, Hagström E, Held C, Kleber ME, Koenig W, März W, Stewart RAH, White HD, Åberg M, Siegbahn A. PLoS Med. 2021 Jan 13;18(1):e1003513. doi: 10.1371/journal.pmed.1003513. eCollection 2021 Jan. PMID: 33439866.
Erin Morton (Other)
2021Activity: Other activity types › Other
-
Professor Christian Mueller discussing the RAPID TnT trial at the European Society of Cardiology Congress 2019
Erin Morton (Other)
2019Activity: Other activity types › Other
-
Professor Derek Chew discussing the RAPID TnT trial for the European Society of Cardiology TV 2019
Erin Morton (Other)
2019Activity: Other activity types › Other
-
Professor Derek Chew presenting the RAPID TnT trial on the main stage at the European Society of Cardiology 2019
Erin Morton (Other)
2019Activity: Other activity types › Other
-
Progression of glucose-lowering diabetes therapy in TECOS. Bethel MA, Engel SS, Stevens SR, Lokhnygina Y, Ding J, Josse RG, Alvarsson M, Hramiak I, Green JB, Peterson ED, Holman RR; TECOS Study Group. Endocrinol Diabetes Metab. 2018 Dec 22;2(1):e00053. doi: 10.1002/edm2.53. eCollection 2019 Jan. PMID: 30815579
Erin Morton (Other)
2019Activity: Other activity types › Other
-
Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events - A Review on Vorapaxar. Gupta R, Lin M, Mehta A, Aedma SK, Shah R, Ranchal P, Vyas AV, Singh S, Kluck B, Combs WG, Patel NC. Curr Probl Cardiol. 2021 Oct 28:101035. doi: 10.1016/j.cpcardiol.2021.101035. Online ahead of print. PMID: 34718032 Review.
Erin Morton (Other)
2021Activity: Other activity types › Other
-
Redesigning TRACER trial after TRITON. Serebruany VL. Int J Cardiol. 2015 Oct 15;197:44-7. doi: 10.1016/j.ijcard.2015.06.020. Epub 2015 Jun 18. PMID: 26126053
Erin Morton (Other)
2015Activity: Other activity types › Other
-
Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER. White HD, Huang Z, Tricoci P, Van de Werf F, Wallentin L, Lokhnygina Y, Moliterno DJ, Aylward PE, Mahaffey KW, Armstrong PW. J Am Heart Assoc. 2014 Jul 10;3(4):e001032. doi: 10.1161/JAHA.114.001032. PMID: 25012288. Clinical Trial.
Erin Morton (Other)
2014Activity: Other activity types › Other
-
Research Program: Visibility and Technological Solutions for Frail, Homebound and Bedridden People - FHBP
Maria Alejandra Pinero de Plaza (Participant), Penelope McMillan (Participant), Alline Beleigoli (Participant), Michael Lawless (Participant), Alexandra Mudd (Participant), Mandy Archibald (Participant), Matthew Tieu (Participant), Rebecca Feo (Participant), Erin Morton (Participant), Belinda Lange (Participant), Mark Thompson (Participant), Danielle Taylor (Participant), Sue Gordon (Participant), Agustina Gancia (Participant), Sarah Hunter (Participant), Kathy Phelan (Participant), Robyn Clark (Participant), Ricky Buchanan (Participant), Renuka Visvanathan (Participant) & Alison Kitson (Participant)
Jun 2022 → Jun 2026Activity: Other activity types › Other
-
Risk markers of incident atrial fibrillation in patients with coronary heart disease. Tomasdottir M, Held C, Hadziosmanovic N, Westerbergh J, Lindbäck J, Aylward PE, Budaj A, Cannon CP, Engdahl J, Granger CB, Koenig W, Manolis AJ, Oldgren J, Stewart RAH, Svennberg E, Vinereanu D, White HD, Siegbahn A, Wallentin L, Hijazi Z. Am Heart J. 2021 Mar;233:92-101. doi: 10.1016/j.ahj.2020.12.016. Epub 2021 Jan 2. PMID: 33400910 Clinical Trial.
Erin Morton (Other)
2021Activity: Other activity types › Other
-
Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS. Engel SS, Suryawanshi S, Stevens SR, Josse RG, Cornel JH, Jakuboniene N, Riefflin A, Tankova T, Wainstein J, Peterson ED, Holman RR; TECOS Study Group. Diabetes Obes Metab. 2017 Nov;19(11):1587-1593. doi: 10.1111/dom.12983. Epub 2017 Jul 7. PMID: 28432745 Clinical Trial.
Erin Morton (Other)
2017Activity: Other activity types › Other
-
SAHMRI media publication - World-first trial reduces ED wait times and hospital admissions
Erin Morton (Other)
4 Sep 2019Activity: Other activity types › Other